Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTATOC PET/CT vs Octreoscan in Neuroendocrine Tumors
NCT01869725Phase 2Completed
- Start
- Apr 2013
- Primary completion
- Dec 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of gallium Ga 68-edotreotide in Neuroendocrine Neoplasm (NEN), medulloblastoma, neuroblastoma, somatostatinoma. Started Apr 2013; status: completed.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)medulloblastomaneuroblastomasomatostatinoma
Beyond the preview
Go deeper on NCT01869725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01869725.